Day 2 :
CEO & Founder - Biotechnology and Regenera-tive Medicine at RegenerAge International
Keynote: RegenerAge System: Therapeutic effects of combinatorial biologics (Bioquantine®) and Spinal cord stimulation system on a patient with Spinal Cord section
Time : 10:00 - 10:45
CEO & Founder - Biotechnology and Regenera-tive Medicine at RegenerAge International.VP of International Clinical Development for Bioquark, Inc. Chief Clinical Officer at ReAnima™ Advanced Biosciences. Westhill University School of Medicine. Mexico.Advance Fellow by the American Board of An-tiAging and Regenerative Medicine (A4M).Visiting scholar at University of North Carolina at Chapel Hill (Dermatology).Fellow in Stem Cell Medicine by the American Academy of Anti-Aging Medicine and Universi-ty of South Florida.
As it has been previously demonstrated that co-electroporation of Xenopus laevis frog oocytes with normal cells and cancerous cell lines in-duces the expression of pluripotency markers, and in experimental murine model studies that Bioquantine® extract (purified from intra- and extra-oocyte liquid phases of electroporated oocytes) showed potential as a treatment for a wide range of conditions as Squint, Spinal Cord Injury (SCI) and Cerebral Palsy among others. The current study observed beneficial changes with Bioquantine® administration in a patient with a severe SCI. Pluripotent stem cells have therapeutic and regenerative potential in clinical situations CNS disorders even cancer.2-3-7 One method of reprogramming somatic cells into pluripotent stem cells is to expose them to ex-tracts prepared from Xenopus laevis oocytes1 We showed previously that coelectroporation of Xenopus laevis frog oocytes; with normal cells and cancerous cells lines, induces expression of markers of pluripotency.4 We also observed ther-apeutic effects of treatment with a purified ex-tract (Bioquantine) of intra- and extra-oocyte liquid phases derived from electroporated X. laevis oocytes, on experimentally induced pathologies including murine models of melanoma, traumatic brain injury, and experi-mental skin wrinkling induced by squalene-monohydroperoxide (Paylian et al, 2016). The positive human findings for Spinal Cord Injury, and Cerebral Palsy with the results from previ-ous animal studies with experimental models of traumatic brain injury, respectively (Paylian et al, 2016). Because of ethical reasons, legal re-strictions, and a limited numbers of patients, we were able to treat only a very small number of patients. These results indicate that Bioquan-tine® may be safe and well tolerated for use in humans, and deserves further study in a range of degenerative disorders. We propose that the mechanism of action of Bioquantine® in these various diseases derives from its unique phar-macology and combinatorial reprogramming properties. In conclusion, these preliminary find-ings suggest that Bioquantine is safe and well tolerated on patients with Cerebral Palsy and-Spinal Cord Injury, among others. In addition to the regenerative therapy and due to the patient condition, we decided to include the Restore-Sensor SureScan5-6 . Based on the of electrical stimulation for rehabilitation and regeneration after spinal cord injury published by Hamid and MacEwan 8-9 , we designed an improved deliv-ery method for the in situ application of MSCs and Bioquantine® in combination with the RestoreSensor® SureScan® Conclusions: To the present day the patient who suffered a total sec-tion of spinal cord at T12-L1 shows an im-provement in sensitivity, strength in striated muscle and smooth muscle connection, 9 months after the first therapy of cell regeneration and 1 month after the placement of RestoreSensor® at the level of the lesion, the patient with a com-plete medullary section shows an evident im-provement on his therapy of physical rehabilita-tion in standing for the first time and showing a progressively important functionality.